Keywords: first, comparitive, trial, shows, benefit, astrazeneca, arimidex
First comparitive trial shows benefit of AstraZeneca's Arimidex over
Article | 13 December 1999
AstraZeneca says that its anticancer agent Arimidex (anastrozole), anaromatase inhibitor, is more effective than its widely-touted antiestrogen Nolvadex (tamoxifen) in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
